Xue H et al., 2021-12-01: Review of methylene blue as an anti-aging candidate covering neurodegeneration, memory loss, skin aging and progeria, of which nearly all cited human-adjacent evidence is preclinical or small-trial.
This review summarizes the recent studies on the applications of MB in treating age-related conditions, including neurodegeneration, memory loss, skin aging, and a premature aging disease, progeria.
abstract
Xue H et al., 2021-12-01: Review of methylene blue as an anti-aging candidate covering neurodegeneration, memory loss, skin aging and progeria, of which nearly all cited human-adjacent evidence is preclinical or small-trial. Study type: narrative review. N: n/a. Country: USA (University of Maryland). Funder: NHLBI R01 HL126784. Declared conflicts: 'K.C is the founder of Mblue Labs, which is a biotech company that focuses on skincare and public health' – recorded as neutral disclosure; the lead author group also published the MB skin and hair-follicle work. Review only; no primary lifespan data. Also filed as MTJ-07 (claims C1, C3). Study type: review.
